Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
D ThaçiA PinterM SebastianC TermeerMichael SticherlingS GerdesS WegnerS KrampeH BartzC RauschA MenschK EyerichPublished in: The British journal of dermatology (2020)
Guselkumab demonstrated superiority over FAE in systemic-treatment-naive patients with moderate-to-severe plaque psoriasis through 24 weeks.